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The early manifestations of coccidioidomycosis (valley
fever) are similar to those of other causes of community-
acquired pneumonia (CAP). Without specific etiologic test-
ing, the true frequency of valley fever may be
underestimated by public health statistics. Therefore, we
conducted a prospective observational study of adults with
recent onset of a lower respiratory tract syndrome. Valley
fever was serologically confirmed in 16 (29%) of 55 per-
sons (95% confidence interval 16%–44%). Antimicrobial
medications were used in 81% of persons with valley fever.
Symptomatic differences at the time of enrollment had
insufficient predictive value for valley fever to guide clini-
cians without specific laboratory tests. Thus, valley fever is
a common cause of CAP after exposure in a disease-
endemic region. If CAP develops in persons who travel or
reside in Coccidioides-endemic regions, diagnostic evalua-
tion should routinely include laboratory evaluation for this
organism.
C
occidioidomycosis (valley fever) is an infection
caused by Coccidioides immitis or  Coccidioides
posadasii, which are fungi endemic to parts of Arizona,
California, Utah, New Mexico, Texas, Mexico, and else-
where in Central and South America (1). The most com-
mon clinical syndrome resulting from infection is
community-acquired pneumonia (CAP), which is charac-
terized by systemic illness, lower respiratory tract symp-
toms, and various immunologic manifestations such as
rashes and skeletal discomfort (2–5). This syndrome,
which occurs 1–3 weeks after inhalation of a fungal spore,
may be present for protracted periods. Although infection
occasionally spreads hematogenously to other parts of the
body, most infections eventually resolve without compli-
cations or specific antifungal therapy.
Enormous disparities exist between the predicted num-
ber of illnesses caused by coccidioidal infection and the
actual number of infections reported to state departments
of public health. For example, rates of skin test conversion
(6) and the size of the susceptible population in southern
Arizona indicate that illness should develop in ≈30,000
persons per year. Similar frequencies are obtained from
other indirect analyses (7). If these estimates were accu-
rate, coccidioidomycosis would be a common cause of
CAP in this disease-endemic region. In contrast, cases
reported to the Arizona Department of Health Services
from 1998 to 2001 averaged <2,000 annually (8) or 15-
fold fewer than estimated. The figure that best reflects the
actual frequency of illness has profound implications for
diagnostic evaluation and therapeutic management in
patients with exposure to Coccidioides species in a dis-
ease-endemic region.
In this report, we present results of evaluations of
patients seeking care for symptoms of CAP with respect to
the incidence of coccidioidomycosis. Because CAPis often
managed by clinicians as part of general medical practices,
we chose that setting for our studies. Our findings provide
the first prospective evidence that coccidioidomycosis is a
common cause of CAP in the study area. In addition to the
relevance of these results for residents within Coccidioides-
endemic regions, a similar risk for coccidioidal infection
should be expected for others with CAP and a recent travel
history to Coccidioides-endemic areas.
Methods
Study Sample 
Patients were recruited from 3 primary care sites in
Tucson, Arizona: the Urgent Care Center of University
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Community Physicians. Recruitment was conducted dur-
ing 2 time periods: from December 1, 2003, through
February 21, 2004, and from May 1, 2004, through August
14, 2004. Although we sought to enroll as many eligible
persons as possible during these periods, study personnel
were not always available to do so.
To be eligible for enrollment, patients had to exhibit a
lower respiratory syndrome of <1 month’s duration that
included >1 of the following: pleuritic chest pain, dyspnea
on exertion, having an evaluation by a chest radiograph,
multiple visits for the same respiratory problem, or admin-
istration of an antibacterial drug for presumed CAP.
Patients were excluded from enrollment if they had a pre-
viously diagnosed, laboratory-confirmed coccidioidal
infection, another laboratory-confirmed diagnosis for
inclusion-defining illness, were <18 years of age, or had
not had previous exposure >1 week in a disease-endemic
area. Fewer than 5% of the patients offered enrollment
refused to participate in the study.
Study Protocol
This was an observational study, and medical manage-
ment of each patient’s condition remained entirely with the
responsible clinician. After informed consent was
obtained, persons were interviewed and their clinical
records were reviewed to collect information regarding
demographics, comorbid conditions, time ranges of expo-
sure in a disease-endemic region, and recent antimicrobial
therapy for current respiratory illness. Persons were asked
to complete the Medical Outcomes Study 36-Item Short
Form Health Survey (SF-36) (9), the Iowa Fatigue Scale
(10), and a respiratory infection severity scale (11). Results
from chest radiographs and complete blood counts, where
obtained as part of routine medical care, were also record-
ed. A second visit was scheduled for all persons.
Serum samples were obtained at both visits. They were
stored at –70°C until tested at the completion of the study.
Persons identified as having a coccidioidal infection were
also contacted during or within the next 6 months to deter-
mine the status of their illness. 
Serologic Analysis 
Anti-coccidioidal antibodies were measured in the lab-
oratory of 1 of the authors (J.N.G.) by several convention-
al methods. The double immunodiffusion technique was
used to measure tube precipitin–type and complement fix-
ing–type anti-coccidioidal antibodies (12,13). Serum sam-
ples qualitatively positive for complement fixing–type
anti-coccidioidal antibodies were retested quantitatively
(14). Anti-coccidioidal immunoglobulin M (IgM) and IgG
antibodies were measured by enzyme-linked immunoassay
by using a commercial kit according to the manufacturer’s
instructions (Coccidioides EIA-Gold, Meridian
Diagnostics, Cincinnati OH, USA) (15). An optical densi-
ty >0.20 was considered positive. The relative sensitivity
of these tests in patients with coccidioidal pneumonia has
been previously analyzed (15).
Statistical Analysis 
Patient and laboratory data were entered into a database
(Access 2003, Microsoft Corp., Bellingham WA, USA),
and statistical analysis was accomplished with SAS ver-
sion 8.2 (SAS Institute, Inc., Cary, NC, USA). Differences
between groups for categorical variables were compared
with the χ2 test and those for continuous variables were
compared with the Wilcoxon sign-rank test and Wilcoxon
rank-sum test as appropriate. Differences with p values
<0.05 were considered significant.
Results
Of the 56 persons enrolled in this study, 1 did not pro-
vide a serum sample at baseline and was excluded from
analysis. Fifty-five percent of the enrollees were male, and
the median age was 48 years (interquartile range 33–63
years) (Table 1). Most (87%) persons were non-Hispanic
whites, which reflected the demographics of the study-site
sample. Patients with lower respiratory syndromes had a
median of 3 additional inclusion criteria. Individual crite-
ria were evaluation by a chest radiograph (82%), adminis-
tration of an antimicrobial drug (80%), dyspnea on
exertion (56%), pleurisy (44%), and multiple visits for the
same condition (42%).
Frequency of Coccidioidomycosis as a Cause of CAP
Of the 55 persons who provided serum samples at base-
line, 19 provided second serum samples 10–40 days later
(median 18 days). Of these persons, 16 were positive by >1
serologic test (29%, 95% confidence interval [CI]
16%–44%). At baseline, 12 (75%) of the 16 were positive
by multiple assays, and all but 3 had positive results for
multiple serologic tests for both serum samples (Table 2).
Of the remaining 36 persons, all had negative results for all
tests at baseline, and a second serum sample obtained from
12 persons was also nonreactive.
Comparison of Clinical Characteristics 
between Groups
Demographic results for persons with and without val-
ley fever are shown in Table 1. Length of exposure in the
disease-endemic area was significantly shorter for patients
with valley fever than for those who were seronegative (p
= 0.043). The odds ratio for developing coccidioidomyco-
sis in persons with exposure of <10 years to a disease-
endemic area compared to those with a longer exposure
time was 4.11 (95% CI 1.01–16.8). No other significant
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groups. Twenty, 24, and 11 participants had age ranges of
<40 years, 40–64 years, and >65 years, respectively. The
percentage of participants in each of these age groups with
valley fever was 30%, 29%, and 27%, respectively.
Respiratory, systemic, and musculoskeletal symptoms
are shown in Table 3. Only myalgia showed a significant
difference between the 2 groups. The SF-36 survey and
respiratory infection severity scale did not identify addi-
tional differences. However, the Iowa Fatigue Scale survey
median productivity domain score (maximum score = 10
indicates greatest reduction) was 7 for persons with valley
fever compared with 4.5 for all other persons (p = 0.008). 
The proportion of patients in whom a chest radiograph
was obtained was similar between seropositive and
seronegative patients (75% vs. 72%). However, for those
from whom chest radiographs were obtained (n = 40),
abnormalities were significantly more frequent in partici-
pants with valley fever (75% vs. 25%, p = 0.005).
Radiographic abnormalities associated with coccidioidal
infection included pulmonary infiltrates in 88% and hilar
adenopathy in 1 participant. 
Use of Antimicrobial Drugs
Of the 55 persons who were seen in the primary care
setting, 46 (84%) were prescribed antimicrobial medica-
tions; 13 received 2 consecutive courses of treatment, and
1 received 3 consecutive courses of treatment. No differ-
ences were seen between the seropositive and seronegative
groups in either the proportion treated with antimicrobial
drugs (81% vs. 85%) or the proportion treated with multi-
ple courses of drugs (31% vs. 26%).
Follow-up of Persons with Valley Fever
All persons improved in the 6 months after enrollment.
Only 1 received specific antifungal therapy (oral flucona-
zole for 1 month), and none required hospitalization.
Eleven persons with valley fever repeated the symptom
survey and the Iowa Fatigue Scale a median of 22 days
after enrollment. Their responses indicated significant
improvement for cough (p<0.016), fatigue (p<0.0039),
cognition (p = 0.016), energy (p = 0.0015), and productiv-
ity (p = 0.062). Similar improvements were noted with the
SF-36 survey and the Iowa Fatigue Scale readministered to
10 persons at the 6-month follow-up visit. 
Discussion
Of the patients enrolled in our prospective study from
select ambulatory care settings within the disease-endemic
region, 29% were diagnosed serologically as having
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wide 95% CI (16%–44%), this number demonstrates a
high proportion of CAP caused by this infection.
Furthermore, although the serologic tests used for diagno-
sis are highly specific for coccidioidal infection
(12,13,16–18), another study emphasized that in the first
weeks of primary illness these tests frequently show nega-
tive results (15). In the current study, 1 of 13 participants
not initially serologically positive had coccidioidal anti-
bodies in a second serum sample. Twenty-seven persons
serologically negative at enrollment did not return for
retesting; thus, additional coccidioidal infections may have
been identified in this group. Our results will likely pro-
vide an underestimate of the incidence in this group of
patients, further strengthening the conclusion that valley
fever is a common cause of CAP in persons exposed to
Coccidiodes in a disease-endemic area.
The high frequency of valley fever as a cause of CAP
found in this study is consistent with previous estimates of
coccidioidomycosis as a dominant cause of CAP with
exposure in disease-endemic areas. A similar estimate of
25% to 30% has been obtained retrospectively at the
Southern Arizona Veterans Administration Health Care
System in Tucson, Arizona (7). Conversely, a diagnosis of
valley fever requires laboratory testing. That this practice
may not be uniform among clinicians was shown in a ret-
rospective analysis of physician-specific diagnoses at pri-
mary care clinics in Tucson, Arizona, in which the rate of
diagnosing coccidioidomycosis varied between 0% and
25% among physicians within the same group practice (7).
Similar differences might also account for the increasing
case rate associated with patient age that was reported in a
recent analysis of 2001 Arizona state statistics (8). Case
rates for persons >44 years of age were nearly twice those
for persons 21–44 years of age. In our study in which all
persons were uniformly evaluated for valley fever, all age
groups had similar rates (27.3%–30.0%). Furthermore,
although not detailed in our results, severity of illness in
terms of respiratory symptoms was less in elderly subjects.
We interpret the differences between the state statistics and
those of our study as indicating that older persons who
develop an illness are more likely to have an exact diagno-
sis determined, underscoring underreporting of illness in
some patient groups such as young adults.
A corollary to the high frequency of coccidioidomyco-
sis seen in this study is that persons anywhere with CAP
and a history of recent travel to south-central Arizona or
other regions where coccidioidomycosis is highly endem-
ic would be expected to have a similarly high risk. For this
reason, obtaining a travel history for any patient with CAP
is essential for early and accurate diagnosis of this disease,
as well as for other regional problems such as severe acute
respiratory syndrome (SARS), hantavirus pneumonia, and
avian influenza. Although the Infectious Diseases Society
of America practice guidelines for CAP currently recom-
mend obtaining a complete travel history only in patients
with refractory pneumonia (19), we recommend that the
guidelines be revised to recommend obtaining a travel his-
tory at the first evaluation.
Analysis of multiple symptoms at baseline showed sev-
eral characteristics associated with coccidioidal infections.
Both a shorter length of exposure in a disease-endemic
region and a greater frequency of radiographic abnormali-
ties were seen in persons with valley fever compared with
those without valley fever. These associations were also
evident in a previous report from a university health center
(5). Symptoms of myalgia and reduced productivity were
also evident with coccidioidal infection. However, none of
these associations, alone or in combination, were of a suf-
ficient magnitude to assist clinicians in the initial diagno-
sis. Therefore, our findings, as in the previous study (5),
emphasize that laboratory testing at the initial physician
visit is essential to identify patients with symptoms of CAP
that are caused by valley fever.
A high proportion (81%) of persons with valley fever
were prescribed an initial course of antimicrobial drugs. Of
these, 12 patients, 3 of whom were diagnosed with valley
fever, received 2 courses of these drugs. Although diagno-
sis of valley fever by serologic methods is frequently
delayed by 3–5 days, use of antimicrobial drugs could still
be avoided or stopped earlier in patients whose illness is
determined to be caused by Coccidioides species.
The inclusion criteria used in this study were designed
both to be broadly inclusive and to select patients with
more severe illness. As such, they differ in some respects
from commonly used entry criteria for clinical trials of
new antimicrobial drugs as treatment for CAP. For exam-
ple, we chose pleuritic chest pain and dyspnea at rest and
fever as an entry requirement. By using these entry
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who underwent radiographic examination had normal radi-
ographs, which is consistent with results of a previous
study (3), but did not adhere to Infectious Diseases Society
of America or American Lung Association definitions of
pneumonia (19). When comparing our findings to those of
other studies, the way in which patients were selected
should be taken into account. 
Several limitations of our methods deserve emphasis.
Because our inclusion criteria were not standard, compari-
son of our results to those of other studies of CAP is diffi-
cult. Also, we did not have a diagnosis for patients without
valley fever. Since this is a relatively small study, addition-
al expanded studies may be useful, especially to extend
observations to other groups such as children, the elderly,
those requiring hospitalization, and residents elsewhere
within disease-endemic regions. Future studies are also
needed to determine best practices for management of pri-
mary coccidioidal infection and possible therapy with spe-
cific antifungal treatment. Such a high proportion of CAP
caused by Coccidioides species should provide further
impetus to conduct those studies.
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